Drugs / ER2001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07344519 | Jun 2024 → Jun 2025 | Huntington disease | ExoRNA Bioscience | Completed | No outcome recorded |
| Phase 0 | NCT06024265 | Apr 2023 → Jan 2025 | Huntington disease | ExoRNA Bioscience | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT07339514 Comparator | Feb 2025 → Apr 2026 overdue | Huntington disease | ExoRNA Bioscience | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-09-29 | ExoRNA Bioscience | Results 艾码生物通过静脉给药实现CNS靶向递送siRNA治疗，ER2001首次公开FIH/IIT研究进展引起行业关注 exornabio.com ↗
IIT研究已获得的数据显示，ER2001产品的安全性和耐受性良好，10例接受治疗的患者在总体临床量表评分改善明确，特别是在总运动评分、精神状态和认知功能综合改善方面，全部患者的疾病进展在临床研究期间均有所控制或改善。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-09-29 | ExoRNA Bioscience | 艾码生物通过静脉给药实现CNS靶向递送siRNA治疗，ER2001首次公开FIH/IIT研究进展引起行业关注 exornabio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ER2001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07344519 ↗ |
| Route | Intravenous | “ER2001 will be administrated intravenously” NCT06024265 ↗ |